Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07824869) titled 'A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients' on Sept. 13.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: Shanghai Henlius Biotech
Condition:
HER2 + Breast Cancer
Intervention:
Drug: HLX22
Drug: Trastuzumab
Drug: Capecitabine
Drug: Paclitaxel
Drug: Docetaxel
Drug: Eribulin
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollmen...